Highlight
- MUC1-Tn is overexpressed in T-cell acute lymphoblastic leukemia (T-ALL) and serves as an effective target for CAR T cell therapy.
- Linperlisib, a selective PI3Kδ inhibitor, enhances MUC1-Tn CAR T cell cytotoxicity and persistence both in vitro and in xenograft T-ALL models.
- Linperlisib prevents CAR T cell exhaustion through suppression of the EGR1/DUSP2 signaling axis and promotes mitochondrial fusion and respiratory function.
- This combination approach offers a promising strategy to overcome CAR T cell target-mediated fratricide and functional exhaustion in T-ALL treatment.
Study Background
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy with poor outcomes in relapsed and refractory cases. Chimeric antigen receptor (CAR) T cell therapy has revolutionized treatment in certain hematologic cancers but faces unique challenges in T-ALL. Particularly, the expression of shared antigens on both leukemic and normal T cells leads to fratricide, limiting CAR T cell expansion and efficacy. Furthermore, CAR T cells can undergo functional exhaustion, undermining durable anti-tumor responses.
The Mucin1-Thomsen-nouvelle (MUC1-Tn) antigen is a glycoform of MUC1 highly expressed in various malignancies, including T-ALL, but displays restricted expression in normal tissues, suggesting it as a potentially attractive and specific CAR target. Previous studies targeting MUC1 variants in solid tumors have shown promising preclinical efficacy.
Given the role of the PI3Kδ signaling pathway in regulating T cell differentiation, exhaustion, and tumor immunosuppression, modulating this pathway may enhance CAR T cell function. Linperlisib is a selective PI3Kδ inhibitor with established therapeutic potential in lymphoid malignancies but its role in enhancing CAR T cell therapy remains to be elucidated.
Study Design
This preclinical investigation confirmed MUC1-Tn antigen expression on T-ALL cell lines and primary patient-derived bone marrow samples. Using this target, investigators engineered MUC1-Tn-specific CAR T cells and evaluated their efficacy in vitro and in murine xenograft T-ALL models.
The study then assessed the impact of combining MUC1-Tn CAR T cells with the PI3Kδ inhibitor linperlisib. Functional assays measured cytotoxic activity, T cell exhaustion markers, differentiation status, mitochondrial dynamics, respiratory capacity, and persistence. Underlying molecular mechanisms explored included the expression modulation of Dual Specificity Phosphatase 2 (DUSP2) and its upstream regulator Early Growth Response 1 (EGR1).
Key Findings
MUC1-Tn Expression and CAR T Cell Function: MUC1-Tn protein was abundantly expressed on multiple T-ALL cell lines and patient-derived leukemia cells, validating its suitability as a CAR target. MUC1-Tn CAR T cells displayed potent cytotoxic activity in vitro, effectively lysing leukemic cells.
In Vivo Efficacy of MUC1-Tn CAR T Cells: In xenograft mouse models, MUC1-Tn CAR T cells significantly reduced leukemic burden, confirming their anti-leukemic potential.
Enhancement by Linperlisib: Linperlisib co-treatment markedly improved CAR T cell-mediated leukemia control. This was evidenced by increased tumor clearance and prolonged survival in mice. The combined treatment also reduced expression of canonical exhaustion markers such as PD-1, TIM-3, and LAG-3 on CAR T cells.
Reduced Terminal Differentiation and Sustained Functionality: Linperlisib-treated CAR T cells exhibited decreased proportions of terminally differentiated T cells, favoring a memory-like phenotype that supports long-term persistence. These cells maintained sustained tumor control upon rechallenge, indicating durable immunity.
Mitochondrial and Metabolic Effects: Linperlisib promoted mitochondrial fusion and enhanced oxidative phosphorylation capacity in CAR T cells, contributing to improved energy metabolism required for sustained functionality.
Mechanistic Insights – EGR1/DUSP2 Axis Suppression: At the molecular level, linperlisib suppressed the expression of DUSP2, an important regulator of T cell exhaustion, and inhibited its upstream transcription factor EGR1. This signaling inhibition appears central to reversing exhaustion and boosting CAR T cell persistence.
Expert Commentary
The innovative targeting of MUC1-Tn addresses a critical challenge in T-ALL by selecting an antigen with limited fratricide risk. This study’s demonstration that linperlisib enhances CAR T cell anti-leukemic activity by mitigating exhaustion highlights the therapeutic potential of integrating small molecule inhibitors to modulate CAR T cell biology.
Mechanistically, the identification of the EGR1/DUSP2 axis as a modulator of exhaustion adds valuable insight into CAR T cell regulation. This aligns with emerging evidence that PI3Kδ influences T cell differentiation and exhaustion phenotypes. Notably, metabolic reprogramming through mitochondrial fusion supports functional CAR T cell states, underscoring the intersection of signaling and bioenergetics in effective immunotherapy.
Limitations include the preclinical nature of this study and the need for translational research to assess safety, optimal dosing, and efficacy in clinical T-ALL patients. Moreover, the long-term effects of PI3Kδ inhibition on normal immunity warrant consideration.
Conclusion
This study provides compelling preclinical evidence that combining MUC1-Tn-targeted CAR T cell therapy with linperlisib enhances anti-leukemic efficacy and CAR T cell persistence by preventing exhaustion through inhibition of the EGR1/DUSP2 axis. The approach addresses vital limitations in T-ALL CAR therapy related to fratricide and functional decline.
These findings advocate for clinical development of MUC1-Tn CAR T cells with adjunctive PI3Kδ inhibition as a promising strategy in treating T-ALL. Further clinical trials are needed to validate safety and therapeutic benefit in patients, potentially transforming outcomes for this difficult-to-treat leukemia.
Funding and ClinicalTrials.gov
Details on funding sources and clinical trial registrations were not specified in the original publication.
References
- Wei JY, Liu ZW, Lu QS, et al. Linperlisib enhances MUC1-Tn CAR T cell efficacy by inhibiting EGR1/DUSP2 axis to prevent CAR T cell exhaustion. Leukemia. 2026 Jul 3. PMID: 42399625.
- Sterner RC, Sterner RM. CAR-T cell therapy: Current limitations and potential strategies. Blood Cancer J. 2021;11(4):69.
- Brown CE, Mackall CL. CAR T cell therapy: inroads to response and resistance. Nat Rev Immunol. 2019;19(2):73-74.
- Fraser DJ, Rempala GA, Freitas Alexandre Y, et al. T-Cell exhaustion: mechanisms and implications in immunotherapy. Front Immunol. 2021;12:675664.
- Okkenhaug K. Signaling by the phosphoinositide 3-kinase family in immune cells. Annu Rev Immunol. 2013;31:675-704.